Open AccessComparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Author(s) -
Bingqing Huang,
Xiaohong Lin,
Zhicheng Zhang,
Yixi Zhang,
Zhouying Zheng,
Chunlong Zhong,
Xiaoshun He,
Maogen Chen
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002836
Subject(s) - medicine , tacrolimus , methotrexate , hematopoietic stem cell transplantation , gastroenterology , odds ratio , graft versus host disease , transplantation , confidence interval , surgery , immunology
After patients receive hematopoietic stem cell transplantation (HSCT), both cyclosporine (CsA) and tacrolimus (TAC) in combination with methotrexate (MTX) are recommended as the standard prophylaxis strategy for graft versus host disease (GVHD) by the European Group of Blood and Marrow Transplantation. However, the advantage of TAC combined with MTX lacks conclusive evidence.